CDMO News
Mycenax Biotech to Integrate RIN’s Next-Gen ADC Linker into Global CDMO Services
Mycenax Biotech Inc. has entered into a strategic collaboration with Japan-based RIN Institute Inc. through a signed Letter of Intent (LOI), aiming to strengthen its contract manufacturing services in the antibody-drug conjugate (ADC) field. The agreement grants Mycenax and its ADC alliance,
17 June 2025
Stay ahead of trends and best practices
